Correspondence
Edited by Kiriaxos Xenidis and Colin Campbell

Contents
- The case of Stop Smoking Services in England
- Nicotine dependence in patients with schizophrenia
- Methodology and reporting of systematic reviews and meta-analyses

The case of Stop Smoking Services in England

A recent editorial in Nature concerning therapy deficit and the urgent need to invest in research to enhance the effectiveness of psychological treatment is timely and may prove influential for our field.1 The piece used the example of the Improving Access to Psychological Therapies (IAPT) programme and the lack of resources to establish the causes of variation in outcome across a service that provides access to support to more than 600 000 people. We wish to alert interested researchers to a slightly more positive example: the Stop Smoking Services in England. These were established in 1998 to help address the single largest preventable cause of premature death in the country and now treat 800 000 smokers each year. Research has begun on establishing the aspects of support that account for the very large variation that exists between local services2 and specialist practitioners within services.3 The research has found, for example, that group-based treatment is linked to higher success rates than one-to-one treatment or drop-in clinics, and that services which use particular ‘behaviour change techniques’, such as showing smokers their expired-air carbon monoxide readings to boost motivation to stop, have higher success rates.4 This work has led to the development of competence assessment and training programmes (e.g. www.ncsct.co.uk)5 but it is only a beginning. Because it can make use of routinely collected, national data, this kind of research can continue to be carried out extremely cost-effectively and save many thousands of lives. However, significant resources are required to evaluate improved treatment effectively and save many thousands of lives. As rightly pointed out by the authors, this finding is in contrast to a previous study6 carried out in the same area and to other similar studies.7 The reason appears to be the use of the Fagerström Test for Nicotine Dependence (FTND), which has limited psychometric properties in patients with schizophrenia. The authors argue for the validity of the FTND in schizophrenia, by citing the article by Weiberger et al.8 Notwithstanding the methodological superiority of the study in terms of presence of a proper control group, the difficulty of using FTND in people with schizophrenia cannot be denied on a pragmatic basis. It has been widely accepted over the past few decades that dependence is a more holistic concept and cannot be attributed only to the amount or duration of smoking. However, Steinberg et al8 has questioned the relevance of the items of the FTND – such as time to first smoking, difficulty abstaining in forbidden places and frequency of smoking in the first hours after waking up – by means of a factor analysis study in patients with schizophrenia. In fact, modification of the FTND for the serious mentally ill population has been suggested in view of individuals’ frequent impairment in judgement and insight. Such a scale was also useful in Krishnadas et al’s study because all the patients were residents of supported accommodation and there was lack of any objective assessment of nicotine use. Moreover, the emphasis on the amount smoked even in a cross-sectional study like this would have better helped to verify the authors’ statement that ‘those with severe dependence have successfully overcome negative symptoms by increasing their level of nicotine dependence’ (pp. 309–310), although a longitudinal study is essential in settling this issue. We advocate the concept of pack-years in this regard.

The authors adjusted the results for many covariants but left out several important variables which may act as important confounders, such as use of smokeless nicotine, other substance use, presence of physical disorders, type of antipsychotics and other psychotropic medications. They have also not mentioned whether the consent from participants was taken or not. The fact that daily dose of medication was greater in the severely dependent group raises the possibility of a pharmacokinetic interaction or indicates the presence of a poor prognosis subtype with neurobiological underpinnings, which should be clarified in future studies. In Krishnadas et al’s study, the majority of patients were smoking to relax, to socialise better or to alleviate their loneliness, anxiety and depressive symptoms. This makes a strong case for a holistic treatment approach, rather than just prescribing anti-psychotic medication, as many of the mentioned attributing factors can be addressed with a multimodal treatment approach.

Nicotine dependence in patients with schizophrenia

We read with interest the important and clinically relevant study by Krishnadas et al.1 Patients with severe nicotine dependence had greater scores on the positive subscale of the Positive and Negative Syndrome Scale (PANSS) and patients with mild–moderate dependence had greater scores on the PANSS negative subscale compared with non-smokers. As rightly pointed out by the authors, this finding is in contrast to a previous study2 carried out in the same area and to other similar studies.3 The reason appears to be the use of the Fagerström Test for Nicotine Dependence (FTND), which has limited psychometric properties in patients with schizophrenia. The authors argue for the validity of the FTND in schizophrenia, by citing the article by Weiberger et al.4 Notwithstanding the methodological superiority of the study in terms of presence of a proper control group, the difficulty of using FTND in people with schizophrenia cannot be denied on a pragmatic basis. It has been widely accepted over the past few decades that dependence is a more holistic concept and cannot be attributed only to the amount or duration of smoking. However, Steinberg et al5 has questioned the relevance of the items of the FTND – such as time to first smoking, difficulty abstaining in forbidden places and frequency of smoking in the first hours after waking up – by means of a factor analysis study in patients with schizophrenia. In fact, modification of the FTND for the serious mentally ill population has been suggested in view of individuals’ frequent impairment in judgement and insight. Such a scale was also useful in Krishnadas et al’s study because all the patients were residents of supported accommodation and there was lack of any objective assessment of nicotine use. Moreover, the emphasis on the amount smoked even in a cross-sectional study like this would have better helped to verify the authors’ statement that ‘those with severe dependence have successfully overcome negative symptoms by increasing their level of nicotine dependence’ (pp. 309–310), although a longitudinal study is essential in settling this issue. We advocate the concept of pack-years in this regard.

The authors adjusted the results for many covariants but left out several important variables which may act as important confounders, such as use of smokeless nicotine, other substance use, presence of physical disorders, type of antipsychotics and other psychotropic medications. They have also not mentioned whether the consent from participants was taken or not. The fact that daily dose of medication was greater in the severely dependent group raises the possibility of a pharmacokinetic interaction or indicates the presence of a poor prognosis subtype with neurobiological underpinnings, which should be clarified in future studies. In Krishnadas et al’s study, the majority of patients were smoking to relax, to socialise better or to alleviate their loneliness, anxiety and depressive symptoms. This makes a strong case for a holistic treatment approach, rather than just prescribing anti-psychotic medication, as many of the mentioned attributing factors can be addressed with a multimodal treatment approach.

Declaration of interest

R.W. undertakes research and consultancy and receives fees for speaking from companies that develop and manufacture smoking cessation medications (Pfizer, Johnson & Johnson, McNeil, GlaxoSmithKline, Nabi, Novartis, and Sanofi-Aventis). He also has a share of a patent for a novel nicotine delivery device.

5 GlaxoSmithKline, Nabi, Novartis, and Sanofi-Aventis. He also speaks from companies that develop and manufacture smoking cessation medications (Pfizer, Johnson & Johnson, McNeil, GlaxoSmithKline, Nabi, Novartis, and Sanofi-Aventis). He also has a share of a patent for a novel nicotine delivery device.

R.W. undertakes research and consultancy and receives fees for speaking from companies that develop and manufacture smoking cessation medications (Pfizer, Johnson & Johnson, McNeil, GlaxoSmithKline, Nabi, Novartis, and Sanofi-Aventis). He also has a share of a patent for a novel nicotine delivery device.

theoretically correct or possible. At a pragmatic level, a measure dependence to a few simple meaningful factors may not be caution. In addition, as Basu & Nebhinani rightly point out, non-psychiatric samples. Such studies should be interpreted with have shown inconsistent factor structure for the FTND, even in one of the reasons why studies that have used such approaches to that of Radzius et al, explaining 53% of the total variance. The first factor reflected the degree of urgency to restore nicotine levels after night-time abstinence, and the second factor reflected the persistence with which nicotine levels are maintained during waking hours, thereby tapping into different domains of nicotine dependence itself. This is in contrast to Steinberg et al, who found two factors that were non-meaningful. In addition to other limitations acknowledged by Steinberg et al, exploratory factor analysis techniques have a number of methodological concerns. Most importantly, interpreting the results of any exploratory analyses like principal components analysis is heuristic and may not necessarily reflect the truth in the given data. This is probably one of the reasons why studies that have used such approaches have shown inconsistent factor structure for the FTND, even in non-psychiatric samples. Such studies should be interpreted with caution. In addition, as Basu & Nebhinani rightly point out, reducing a complex, overlapping and holistic concept such as dependence to a few simple meaningful factors may not be theoretically correct or possible. At a pragmatic level, a measure such as pack-years (which only measures amount and duration of smoking) may be a useful measure of lifetime nicotine consumption. We are, however, unaware of any studies that have validated the FTND (or its modifications) or pack-years using a gold standard diagnostic criterion for nicotine dependence in the schizophrenia population. The closest we came was Patkar et al, who found a significant correlation ($r = 0.89$) between the FTND scores and DSM-IV diagnosis of nicotine dependence. Although it is possible that psychopathology may have affected the FTND scores, in our study, the scale administration was facilitated by two clinicians (S.S. and S.T.) thereby lending some objectivity to the measurement.

All participants gave written informed consent. We considered antipsychotic type as a covariate in the model. With regard to other potential confounding factors, our relatively small sample size meant that we did not have enough power to stratify the sample or to add more covariates into the model. It should, however, be noted that adding variables that may themselves significantly covary with nicotine dependence (independent variable) – such as smokeless nicotine/substance use and physical comorbidity – would, in view of controlling for their effects, have decreased the variance explained by nicotine use itself and therefore have been deemed inappropriate in this setting.\footnote{1}

\begin{itemize}
  \item Steinberg ML, Williams JM, Steinberg HR, Krejci JA, Ziedonis DM. Applicability of the Fagerström Test for Nicotine Dependence in smokers with schizophrenia. \textit{Addict Behav} 2005; 30: 49–59.
  \item Rummel RJ. \textit{Applied Factor Analysis}. Northwestern University Press, 1970.
  \item Patkar AA, Gopalakrishnan R, Lundy A, Leone FT, Certa KM, Weinstein SP. Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. \textit{J Nerv Ment Dis} 2002; 190: 604–10.
\end{itemize}

\textbf{Authors’ reply:} We agree with Basu & Nebhinani that recent studies have questioned the psychometric properties of the FTND in this population. Indeed, as Steinberg et al suggest, we may have underestimated nicotine dependence by using the FTND.\footnote{1} We acknowledged this shortcoming in the article. We conducted a principal components analysis on our data-set, in accordance with Steinberg et al. Our results revealed a two-factor structure similar to that of Radzius et al, explaining 53% of the total variance. The first factor reflected the degree of urgency to restore nicotine levels after night-time abstinence, and the second factor reflected the persistence with which nicotine levels are maintained during waking hours, thereby tapping into different domains of nicotine dependence itself. This is in contrast to Steinberg et al, who found two factors that were non-meaningful. In addition to other limitations acknowledged by Steinberg et al, exploratory factor analysis techniques have a number of methodological concerns. Most importantly, interpreting the results of any exploratory analyses like principal components analysis is heuristic and may not necessarily reflect the truth in the given data.\footnote{2} This is probably one of the reasons why studies that have used such approaches have shown inconsistent factor structure for the FTND, even in non-psychiatric samples. Such studies should be interpreted with caution. In addition, as Basu & Nebhinani rightly point out, reducing a complex, overlapping and holistic concept such as dependence to a few simple meaningful factors may not be theoretically correct or possible.\footnote{3} At a pragmatic level, a measure such as pack-years (which only measures amount and duration of smoking) may be a useful measure of lifetime nicotine consumption. We are, however, unaware of any studies that have validated the FTND (or its modifications) or pack-years using a gold standard diagnostic criterion for nicotine dependence in the schizophrenia population. The closest we came was Patkar et al, who found a significant correlation ($r = 0.89$) between the FTND scores and DSM-IV diagnosis of nicotine dependence.\footnote{5} Although it is possible that psychopathology may have affected the FTND scores, in our study, the scale administration was facilitated by two clinicians (S.S. and S.T.) thereby lending some objectivity to the measurement.

All participants gave written informed consent. We considered antipsychotic type as a covariate in the model. With regard to other potential confounding factors, our relatively small sample

\begin{itemize}
  \item Steinberg ML, Williams JM, Steinberg HR, Krejci JA, Ziedonis DM. Applicability of the Fagerström Test for Nicotine Dependence in smokers with schizophrenia. \textit{Addict Behav} 2005; 30: 49–59.
  \item Rummel RJ. \textit{Applied Factor Analysis}. Northwestern University Press, 1970.
  \item Patkar AA, Gopalakrishnan R, Lundy A, Leone FT, Certa KM, Weinstein SP. Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. \textit{J Nerv Ment Dis} 2002; 190: 604–10.
\end{itemize}

Methodology and reporting of systematic reviews and meta-analyses
Fred Lerner and Jessica L. Hamblen
BJP 2013, 202:75-76.
Access the most recent version at DOI: 10.1192/bjp.202.1.75a

This article cites 2 articles, 1 of which you can access for free at:
http://bjp.rcpsych.org/content/202/1/75.2#BIBL

To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at /letters/submit/bjprcpsych;202/1/75-a

http://bjp.rcpsych.org/ on July 8, 2017
Published by The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to:
http://bjp.rcpsych.org/site/subscriptions/